X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
mRNA-3927 is a novel, IV-administered, lipid nanoparticle (LNP)-encapsulated dual investigational mRNA therapy that encodes for PCCA and PCCB subunit proteins. It is being evaluated for the treatment of propionic acidemia.
Lead Product(s): mRNA-3927
Therapeutic Area: Genetic Disease Product Name: mRNA-3927
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 03, 2024
Details:
The net proceeds will be used to fund Moderna’s influenza program, including mRNA-1010, a quadrivalent seasonal influenza vaccine encoding hemagglutinin (HA) glycoproteins of four flu strains administered intramuscularly.
Lead Product(s): mRNA-1010
Therapeutic Area: Infections and Infectious Diseases Product Name: mRNA-1010
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Blackstone Life Sciences
Deal Size: $750.0 million Upfront Cash: Undisclosed
Deal Type: Financing March 27, 2024
Details:
mRNA-1647 is an investigational mRNA-based vaccine against CMV consisting of 6 mRNA sequences encoding 2 CMV antigens (glycoprotein B and the pentameric glycoprotein complex). It is being evaluated for the treatment of cytomegalovirus infection.
Lead Product(s): mRNA-1647
Therapeutic Area: Infections and Infectious Diseases Product Name: mRNA-1647
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 27, 2024
Details:
Moderna's primary product candidate, Spikevax, is currently undergoing Phase III clinical trials for the purpose of actively immunizing individuals to prevent COVID-19.
Lead Product(s): Covid-19 Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Spikevax
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 26, 2024
Details:
mRNA-4359 is a checkpoint cancer vaccine candidate that expresses Indoleamine 2,3-dioxygenase (IDO) and programmed death-ligand 1 (PD-L1) antigens. It is being evaluated in phase 1/2 clinical trials for the treatment of advanced solid tumors.
Lead Product(s): mRNA-4359,Pembrolizumab
Therapeutic Area: Oncology Product Name: mRNA-4359
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 05, 2024
Details:
The collaboration brings together Carisma's chimeric antigen receptor macrophage (CAR-M) platform with Moderna's messenger RNA (mRNA) and lipid nanoparticle (LNP) technologies to generate and develop in vivo CAR-M therapeutics for oncology.
Lead Product(s): CAR-M-based Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Recipient: Carisma Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 14, 2023
Details:
V940 (mRNA-4157) is a novel investigational messenger RNA (mRNA)-based individualized neoantigen therapy (INT) consisting of a synthetic mRNA coding for up to 34 neoantigens. It is under phase 2 clinical development for the treatment of high-risk stage III/IV Melanoma .
Lead Product(s): mRNA-4157,Pembrolizumab
Therapeutic Area: Oncology Product Name: V940
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2023
Details:
V940 (mRNA-4157) is a novel investigational messenger RNA (mRNA)-based individualized neoantigen therapy (INT) consisting of a synthetic mRNA coding for up to 34 neoantigens. It is under phase 2 clinical development for the treatment of non-small cell lung cancer.
Lead Product(s): mRNA-4157,Pembrolizumab
Therapeutic Area: Oncology Product Name: V940
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 11, 2023
Details:
New partnership will harness Moderna's mRNA rapid-response platform, clinically validated during the COVID-19, to accelerate epidemic and pandemic vaccine development. First project will enable rapid pre-clinical testing of antigen designs for high-risk viral families.
Lead Product(s): mRNA Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Vaccine
Partner/Sponsor/Collaborator: CEPI
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership October 30, 2023
Details:
Under the agreement, Moderna will leverage Caris' library of de-identified, multi-modal data solutions to enhance Moderna's oncology pipeline, including facilitation of optimal clinical trial design, discovery of novel biomarkers and characterization of resistance mechanisms.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Recipient: Caris Life Sciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 24, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
